Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 7, 2015, Pages 671-685

  Sterling, R K ^a   Kuo, A ^b   Rustgi, V K ^c   Sulkowski, M S ^d   Stewart, T G ^e   Fenkel, J M ^f   El Genaidi, H ^g   Mah'Moud, M A ^h   Abraham, G M ⁱ   Stewart, P W ^e   Akushevich, L ^e   Nelson, D R ^j   Fried, M W ^e   Di Bisceglie, A M ^k  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Metropolitan Liver and Gastroenterology Center   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^g OUR LADY OF LOURDES MEDICAL CENTER   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ SAINT VINCENT HOSPITAL   (United States)

^j UNIVERSITY OF FLORIDA   (United States)

^k SAINT LOUIS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; BOCEPREVIR; HEMOGLOBIN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2B; PROLINE; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ALGORITHM; ARTICLE; BILIRUBIN BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RESPONSE GUIDED THERAPY; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIRUS TYPING; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMORBIDITY; DRUG COMBINATION; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALGORITHMS; ANTIVIRAL AGENTS; BIOMARKERS; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; YOUNG ADULT;

EID: 84926150559     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13095     Document Type: Article

References (30)

1. Te HS, Jensen DM,. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1-21, vii.
2. Alter MJ,. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-41.
3. Rustgi VK,. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007; 42: 513-21.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
5. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
7. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
8. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
9. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
10. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
11. Ogawa E, Furusyo N, Nakamuta M, et al,. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther 2013; 38: 1076-85.
12. Jacobson IM, Marcellin P, Zeuzem S, et al,. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 2012; 56: 567-75.
13. Ramachandran P, Fraser A, Agarwal K, et al,. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35: 647-62.
14. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM,. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-38.
15. Nelson DR, Davis GL, Jacobson I, et al,. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2009; 7: 397-414; quiz 366.
16. Marcellin P, Boyer N, Gervais A, et al,. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-81.
17. Bruno S, Stroffolini T, Colombo M, et al,. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
18. Alberti A,. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int 2011; 31 (Suppl. 1): 18-22.
19. Veldt BJ, Heathcote EJ, Wedemeyer H, et al,. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
20. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA,. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014; 39: 93-103.
21. Butt AA, Kanwal F,. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012; 54: 96-104.
22. Saxena V, Manos MM, Yee HS, et al,. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther 2014; 39: 1213-24.
23. Fevery B, Susser S, Lenz O, et al,. HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy. Antivir Ther 2014; 19: 559-67.
24. Vermehren J, Aghemo A, Falconer K, et al,. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J Hepatol 2014; 2014: 913-9.
25. Liu J, Jadhav P, Amur S, et al,. Response guided telaprevir therapy in prior relapsers: the role of bridging data from treatment-naïve and experienced subjects. Hepatology 2013; 57: 857-902.
26. Gordon SC, Muir AJ, Lim JK, et al,. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real-world experience from HCV-TARGET. J Hepatol 2014; 62: 286-93.
27. Hézode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-41.
28. Maasoumy B, Cobb B, Bremer B, et al,. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther 2014; 39: 85-92.
29. Gordon SC, Yoshida EM, Lawitz EJ, et al,. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther 2013; 38: 16-27.
30. Donepudi I, Parades A, Hubbard S, Awad C, Sterling RK,. Utility of evaluating HCV in an Uninsured population. Dig Dis Sci 2014; 1-6.